


SECOND ANNOUNCEMENT



36th BMCS Spring Symposium on
Medicinal Chemistry

Thursday 24th April 2025
Fielder Centre, Hatfield, UK



Synopsis:

Known colloquially as the “Hatfield MedChem” meeting, this is a highly successful, long-standing, one-day meeting that runs annually. The scientific program will comprise presentations and posters showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics at the forefront of drug discovery. The meeting aims to be informal and interactive, and is ideal for all those working in medicinal chemistry and drug discovery more widely.

Programme:

09:00 Registration/Coffee

09:30 Welcome and Introduction

09:35 **Discovery of Orally Available, Brain Penetrant mPTP Blockers**
Gilles Ouvre (NRG) – 40 mins

10:15 **High-Throughput Synthesis Strategies for Unlocking Novel E3 Ligase Ligands in Targeted Protein Degradation**
Maxime Rouah (GSK) – 40 mins

10:55 Tea/Coffee, Posters and Exhibition

11:25 **Therapeutic Opportunities for Fatty Liver Disease with Isoform-selective Cyclophilin Inhibitors**
Julien Michel (University of Edinburgh) – 25 mins

11:50 **Hop to it! The Discovery of a Novel, Potent Series of ROCK Inhibitors by Scaffold Hopping**
David Clark (Charles River) – 25 mins

12:15 **Optimisation of lysyl-t-RNA Synthetase Inhibitors as Antimalarials**
Barbara Forte (Dundee Drug Discovery Unit) – 25 mins

12:40 Lunch, Posters and Exhibition

13:50 **Capps Green Zomaya Award Lecture: Discovery and Clinical Progression of a Novel Therapy for the Treatment of Muscular Dystrophy**
Paul Winship (Charles River) – 25 mins

14:15 **Discovery of ASTX295: A Bone-marrow Sparing MDM2 Antagonist from Concept to Clinic**
Steven Howard (Astex) – 40 mins

14:55 **Discovery and In Vitro Assessment of First-in-Class Activin Receptor-Like Kinase 2 Degraders**
Daniel Webb (Charles River/University of Strathclyde) – 25 mins

15:20 Tea/Coffee, Posters and Exhibition

15:55 **The Discovery of an Orally Bioavailable Benzimidazole-derived Small Molecule Inhibitor of IL-17A**
James Reuberson (UCB) – 30 mins

16:25 **Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer**
Coura Diène (AstraZeneca) – 25 mins

16:50 Concluding Remarks

16:55 Meeting close

Organising Committee:

Adrian Hall, *UCB* (Chair)

David Hirst, *MSD*

Alison Jones, *Charles River*

Douglas Williamson, *Nxera Pharma* (Treasurer)

Secretariat contact:

Hg3 Conferences

events@hg3.co.uk

+44 (0) 1423 529333

To find out more, visit the BMCS website by using the URL or by scanning the QR code here:

<https://www.rscbmcs.org/events/hatfield25/>



SCAN ME